OncoMatch

OncoMatch/Clinical Trials/NCT05903833

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Is NCT05903833 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Lenvatinib for recurrent vulvar cancer.

Phase 2RecruitingAGO Research GmbHNCT05903833Data as of Sep 2026Location: Germany

Treatment: Pembrolizumab · LenvatinibEvaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Pembrolizumab

Targeted therapy

Lenvatinib

Cancer type

Cervical Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Female only

Prior therapy

Max 2 prior lines

Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy

Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)

Lab requirements

Blood counts

Adequate organ function as defined in Table 3 of study protocol

Kidney function

Adequate organ function as defined in Table 3 of study protocol

Liver function

Adequate organ function as defined in Table 3 of study protocol

Adequate organ function as defined in Table 3 of study protocol. Specimens must be collected within 10 days prior to the start of study treatment.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05903833 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy disqualifies patients from enrollment.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify